Duke Researchers Link Brain Tumor Drug Resistance To Mismatch Repair Deficiency

July 15, 1997

DURHAM, N.C. -- The failure of chemotherapy to stop glioblastoma, an aggressive brain tumor, may be linked to a deficiency in a naturally occurring "fix-it" material in the cell, according to Duke University Medical Center researchers.

In a study reported in the July 15 issue of Cancer Research, Duke cancer and biochemistry specialists found that glioblastoma multiforme (GBM) tumors that had become resistant to chemotherapeutic agents showed defects in the cellular mismatch repair system, a key factor in quelling cancer cells. The findings reinforce researchers' beliefs that mismatch repair has broad impact on human tumor cell production.

"This study extends results that have been observed in tissue culture cells to human tumors in animals," said Paul Modrich, Ph.D., a Howard Hughes investigator in biochemistry at Duke and lead author of the study. "It renders it likely that this drug resistance is also a significant effect in cancer patients."

Dr. Henry Friedman, chief of pediatric neuro-oncology at Duke and primary investigator of the study funded by the National Institutes of Health, said the research may quickly lead to more effective treatment of GBM, one of the most common and virulent brain tumors.

"The major problem in the treatment of cancer is drug resistance," Friedman said. "Tumor cells become resistant, or could be resistant at diagnosis. The cells escape the effects of the drug, repopulate, and the patient ultimately succumbs to the tumor. If we can determine the mechanisms of resistance to a drug, then we can opt for different therapy or, eventually, alter that mechanism of resistance."

While growing human GBM tumors on mouse models, the researchers treated the tumors with procarbazine, a drug commonly prescribed alone or in combination with other drugs in therapy for the brain cancer. Though procarbazine is a frontline drug treatment, most patients ultimately develop resistance to it and it ceases to check tumor growth. The tumors growing on mice developed resistance to the drug after nine serial treatments, giving the researchers a way to study the resistance mechanism.

Procarbazine is a methylator, an agent that poisons cancer cells by attaching a chemical compound called a methyl group to DNA. In the normal sequence of cell replication, the attached compounds alert the mismatch repair mechanism in the cell that a mutation has occurred, according to Friedman. That triggers a "toxic event," and ultimate destruction of the tumor cell.

"All cells go through changes, or mutations, day to day. It's normal in cell reproduction, and it's the job of mismatch repair material -- which is a family of proteins -- to correct some of the disorder that occurs in cell replication," Friedman said. "What we found was that the resistant tumor cells had a mutation in mismatch repair that was not present in the 'parent' tumor -- the tumor graft that didn't seem to be resistant to drugs at first. We think the resulting deficiency led to the resistance to procarbazine and other methylators."

"Mismatch repair's function is mutation avoidance; it corrects errors and prevents mutations, but it also targets certain DNA-damaging cells to die if exposed to certain agents," Modrich said. "When mismatch repair is inactivated, you predispose cells to a high mutation rate."

This summer, Friedman and Modrich will begin studying the mismatch repair activity in patients' biopsied malignant GBM. If the findings from the xenograft, or animal-grown, tumors bear out, clinical application could begin in trials in the next year, Friedman said.

"It may soon be possible to analyze the patient's tumor at biopsy to determine the likelihood of resistance to the methylators, and to tailor treatment accordingly to reduce tumor progression, and that means faster, more effective treatment," Friedman said.

Other researchers on the project are Stewart Johnson, Qing Dong, Clifford Schold, Ahmed Rasheed, Dr. Sandra Bigner, Francis Ail-Osman, Eileen Dolan, Dr. Michael Colvin, Peter Houghton, Glen Germain, James Drummond, Stephen Keir, Susan Marcelli and Dr. Darell Bigner.
-end-


Duke University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.